A new platelet-inspired helper to control bleeding for people on antiplatelet medicines
Official title: A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet Agents
Funded at Haima Therapeutics, LLC · NIH-11371237 · Data updated 2026-11-12
A new platelet-inspired technology aims to restore normal clotting in people who take antiplatelet drugs, helping reduce bleeding during surgery or trauma.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Haima Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 15, 2025 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $978,218 |
| NIH project number | 5R44HL180258-02 |
| Project ID | NIH-11371237 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at risk of bleeding due to antiplatelet therapy who may require urgent surgery or experience trauma.
✕Less likely to help
Patients not on antiplatelet therapy or without bleeding risk related to such drugs may not benefit from this technology.
What this research studies
This project develops a novel, platelet-inspired nanotechnology designed to counteract the bleeding risk caused by antiplatelet medicines like clopidogrel and ticagrelor. Researchers will work with preclinical models to test how the nanotechnology can quickly promote hemostasis when antiplatelet therapy is present. The approach focuses on creating a donor-independent option that could replace or supplement current blood products and reversal strategies. If successful, it could shorten hospital stays and reduce bleeding-related complications for patients needing urgent procedures.
Why it matters
Potential benefit: If proven effective, patients on antiplatelet therapy could experience safer surgeries and better management of bleeding without relying on donor blood products.
How similar studies have gone: Preliminary work in platelet-inspired or nanotechnology-based hemostatic approaches shows promise, but this specific donor-independent strategy is still in early stages.
Where this research is happening
-
Haima Therapeutics, LLC
Cleveland, United States Active
Researchers
- Principal investigator: Sekhon, Ujjal Didar Singh — Haima Therapeutics, LLC
- Study coordinator: Sekhon, Ujjal Didar Singh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.